Furthermore, the relatively high predictive power of routine biomarkers (OCB, CSF leukocytes, and IgG index, optimism-corrected ROC area of 0.82) and candidate biomarkers (CSF IL-10, CXCL13, and NF-L, optimism-corrected ROC area of 0.87) suggests these combinations may differentiate MS-ON from ION. The gene discussed is NEFL; the disease is myeloid sarcoma.